The Alpha Genesis Primate Research Center, the Research Division of Alpha Genesis Incorporated, is to take on additional European business commitments as the firm continues its expansion efforts on the continent.
In early June 2018, the Russian Ministry of Industry and Trade issued to OBL Pharm the Conclusion GMP-0144-000263/18 on compliance with the requirements of the good manufacturing practice (GMP of the Russian Federation).
Epigen Biosciences entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease.
The cluster was established in order to combine the competencies of its participants to perform non-clinical studies on medical and environmental safety in accordance with the principles of Good Laboratory Practice.
Advaxis, a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential.
Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
Kineta announced that it has entered into an exclusive option and license agreement with Genentech to develop Kineta's α9/α10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain.
Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.